Dr Reddy’s Labs Q4 FY25 Earnings: Hyderabad-based drug maker Dr Reddy’s Laboratories (DRL) on Friday reported a consolidated net profit of Rs 1,593.9 crore for the quarter ended March 31, an increase of 22 per cent over the corresponding period a year ago that exceeded analysts’ expectations. Its revenue grew 20.1 per cent to Rs 8,506 crore for the final three months of FY25, according to a regulatory filing.
Both profit and sales beat Street estimates. According to Zee Business research, DRL was estimated to register a net profit of Rs 1,430 crore and revenue of Rs 8,435 crore.
Dr Reddy’s Q4 FY25 Results | How the company performed operationally
The pharmaceutical firm clinched earnings before interest, taxes, depreciation and amortisation (EBITDA) of Rs 2,474.9 crore for the March quarter, meeting the mark in terms of analysts’ expectations.
Zee Business analysts had pegged the company’s EBITDA at Rs 2,250 crore.
The drug maker said the EBITDA contributed 29.1 per cent to its revenue.
Its margin, a key measure of profitability, came in at 29.1 per cent for the March quarter.
The analysts had pegged its margin at 26.7 per cent.
DRL dividend per share
The pharmaceutical company declared a final dividend of Rs 8 per share for FY25.
Dr Reddy’s Labs management commentary
“We achieved double-digit growth across our businesses, driven by successful product launches, increased revenues from key products in the US and the integration of the acquired NRT business,” said GV Prasad, Co-Chairman and MD, Dr Reddy’s Labs.
“We will continue to strengthen and grow our core businesses through portfolio management and operational excellence, while pursuing strategic partnerships and inorganic growth opportunities,” said Prasad.
DRL Q4 Earnings | Segment revenue
Revenue from the company’s pharma services and active ingredients unit grew 1.3 per cent to Rs 1,167.5 crore while that from its global generics business increased 23.2 per cent to Rs 75,365 crore, according to the filing.
